Assessing ILD in Rheumatology Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in their patients. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/aAuxbJBxBn

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF

Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF multibiomarker scores higher in RA-ILF vs RA alone. Highest quartile had ~2 fold incr risk of prevalent & incident ILD https://t.co/vYg9iB4EtH https://t.co/5ZZx6gg7A4

Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt

Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk

Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/ZeI9z4Civa https://t.co/LCI6kZ1z0v

Did Hydroxychloroquine Reduce COVID-19 Mortality? A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on https://t.co/BuHoMDwpuP

Comparative Frequency of Systemic autoimmune rheumatic diseases (SARDs) in Australia: - SLE 57.9 per 100K - Lupus nephritis 11.2 per 100K - SSc 25.6 per 100K - ANCA-associated vasculitis 10.8 per million PYs https://t.co/cx9LvswQ2E https://t.co/ltcXCw23bI

Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/7UPFd2dSZU

Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N

Single-center retrospective study 49 pts w/ primary angiitis CNS (PACNS) stratified by vessel size. Vessel size dx by imaging & neuroradiologists. Small vessel involv(n  9) was significantly assoc w/ +Biopsies, CTX use, functional decline & more relapses. https://t.co/DF6DknoPxY https://t.co/puc6nvEAut

Systematic review of 139 RCTs(9644 pts) & 12 Rx options for knee OA (KOA) shows simple Rx is best. For pain and function, knee brace was best, followed by exercise, and US worst. For total WOMAC best was hydrotherapy, then exercise & LaserTx. (Short wave diathermy worst) https://t.co/sN9TxJGn6N